Current status and prospects of personalized medicine in patients with inflammatory bowel disease

Czech version

Authors: M. Lukáš
Authors‘ workplace: Klinické a výzkumné centrum pro střevní záněty, ISCARE a. s. a 1. LF UK, Praha
Published in: Gastroent Hepatol 2026; 80(1): 44-48
Category: IBD: Review Article
doi: https://doi.org/10.48095/ccgh202644

Overview

Introducing new drugs in Crohn’s disease and ulcerative colitis has been a regular and broad framework in the last few years. Since 2024, monoclonal antibodies targeting IL-23 are particularly associated with robust expectations. Currently, we have no relevant biological, genetic or molecular markers for disease and therapeutic prognostication. Promising approaches might be in tight monitoring of therapeutic trajectories and searching for minimal residual histologic disease parameters. Patients with a very prompt and fast therapeutic response after therapy initiation have better long-term outcomes in terms of sustained remission and normalisation of quality of life.

Keywords:

Crohn’s disease – ulcerative colitis – advanced therapy – therapeutic trajectories – biomarkers

Sources

1. Tsai L, Ma C, Dulai PS et al. Cotemporary risk of surgery in patients with ulcerative colitis and Crohn‘s disease: a meta-analysis of population-based cohorts. Clin Gastroenterol Hepatol 2021; 19 (10): 2031–2045. doi: 10.1016/j.cgh.2020.10.039.

2. Schmidt H, Billmeier U, Dieterich W et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistence to anti-TNF therapy in Crohn‘s disease. Gut 2019; 68 (5): 814–828. doi: 10.1136/gutjnl-2017-315671.

3. Lee HH, Yuan Y, Boland BS et al. Efficacy of advanced therapies in achieving remission by disease location in Crohn‘s disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2025; 23: S1542-3565 (25) 00615-9. doi: 10.1016/j.cgh.2025.07.009.

4. Parigi TL, D‘Amico F, Abrue MT et al. Difficult to treat inflammatory bowel disease: results from an international consensus meeting. Lancet Gastroenterol Hepatol 2023; 8 (9): 853–859. doi: 10.1016/S2468-1253 (23) 00154-1.

5. Noor NM, Lee JC, Bond S et al. A biomarker-stratified comparison of top down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn‘s disease (PROFILE): a multicentre, open-label randomized controlled trial. Lancet Gastroenterol Hepatol 2024; 9 (5): 415–427. doi: 10.1016/S2468-1253 (24) 00034-7.

6. Turner D, Ricciuto A, Lewis A et al. STRIDE-II: an update on selecting therapeutics targets in inflammatory bowel disease (STRIDE) initiative of the International Organisation for the Study of IBD (IOIBD): determining therapeutics goals for treat to target strategies in IBD. Gastroenterology 2021; 160 (5): 1570–1583. doi: 10.1053/ j.gastro.2020.12.031.

7. Schreiber S, Aden K, Tran F et al. Rise of precision medicine: can it deliver on its promise in IBD? Gut 2025; 75 (1): 176–188. doi: 10.1136/gut jnl-2023-330000.

8. Eyerich K, Weissenseel P, Pinter A et al. IL-23 with guselkumab potentialy modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind multicenter study in participants with moderate-to-severe plaque type psoriasis (GUIDE). BMJ Open 2021; 11 (9): e049822. doi: 10.1136/bmjopen-2021-049822.

9. Kojanová M, Pejrilová D, Fialová J et al. Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: real world data with up to five years of follow-up in the Czech Republic. Int J Dermatol 2025; doi: 10.1111/ijd.70126.

10. Chanchlani N, Lin S, Bewsea C et al. Mechanisms and management of loss of response anti-TNF therapy for patients with Crohn‘s disease: 3 year data from the prospective, multicentre PANTs cohort study. Lancet Gastroenterol Hepatol 2024; 9 (6): 521–538. doi: 10.1016/S2468-1253 (24) 00044-X.

11. Kang B, Kim ES, Choi S et al. Proactive drug monitoring versus clinical based dosing for endoscopic healing for pediatric Crohn‘s disease receiving infliximab. Clin Gastroenterol Hepatol 2026; 24 (1): 201–209. doi: 10.1016/j.cgh.2025. 04.025.

Doručeno/Submitted: 30. 1. 2026

Přijato/Accepted: 5. 2. 2026

Korespondenční autor

prof. MUDr. Milan Lukáš, CSc., AGAF

Klinické a výzkumné centrum pro střevní záněty

ISCARE a. s. a 1. LF UK, Praha

Českomoravská 19

190 00 Praha 9

milan.lukas@email.cz